LXEO vs MELI · $147.7M cap vs P/E 43, rev $19.01B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus MercadoLibre Inc. (MELI) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
LXEO does not have a complete income-statement cache yet.
Latest reported MELI revenue for 2026-06-30 was $19.01B. Net income was $883.0M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
LXEO currently screens at market cap $147.7M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Not investment advice. Open the LXEO and MELI stock pages for the full models.
Not investment advice.